# A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

> **NCT05776927** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 304 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QVM149
- **DRUG:** Salmeterol Xinafoate / Fluticasone Propionate
- **DRUG:** Placebo to QVM149
- **DRUG:** Placebo to Salmeterol Xinafoate / Fluticasone Propionate
- **DRUG:** Run-In Medication
- **DRUG:** Rescue Medication
- **DEVICE:** Concept 1 Device
- **DEVICE:** Girohaler

## Key facts

- **NCT ID:** NCT05776927
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2028-12-21
- **Final completion:** 2029-12-24
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776927, "A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05776927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*